Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy A case report

被引:8
|
作者
Wang, Li-Xin [1 ]
Chen, Xiaoping [1 ]
Jia, Mingming [2 ]
Wang, Shengdian [2 ]
Shen, Jianliang [1 ]
机构
[1] Navy Gen Hosp PLA, Dept Hematol, Beijing 100048, Peoples R China
[2] Chinese Acad Sci, Inst Biophys, Key Lab Infect & Immun, Beijing, Peoples R China
关键词
arthritis; chimeric antigen receptor (CAR)-T cell therapy; cytokine release syndrome;
D O I
10.1097/MD.0000000000010455
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: Chimeric antigen receptor (CAR)-T cell therapy is a novel type of therapy that is being used in an increasing number of patients with acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is the most common complication following CAR-T treatment, but the current understanding of the clinical manifestations and pathogenesis of CRS is still limited. Patient concerns: A 34-year-old male patient was diagnosed with ALL in June 2015. Complete remission (CR) was achieved after induction chemotherapy. The patient received 8 cycles of consolidation chemotherapy to maintain CR. In May 2017, the patient had recurrent ALL. Induction chemotherapy was given again, but without remission. In October 2017, CAR-T cell therapy was given. On October 14, the patient was pretreated with an FC regimen (fludarabine phosphate 50 mg qd on days 1-3; cyclophosphamide 0.4 g qd on days 1-3). CAR-T cells were infused on October 19 and October 20, with the number of infused cells at 2 x 10(5)/kg and 1 x 10(5)/kg, respectively. On October 25, the patient had a high fever, swelling, and pain in the large joints of the limbs, and joint effusion. Diagnosis: This patient was diagnosed with relapsed ALL, and he developed CRS after CAR-T therapy. Interventions: Tacilizumab (400 mg) was infused after CRS was diagnosed, and another dose of tacilizumab (240 mg) was given 6 days later. The pain was also treated with an analgesic drug. Methylprednisolone (1 mg/kg) was given to treat arthritis of the large joints. Outcomes: The patient's temperature was back to normal within 1 hour following the treatment of tacilizumab, but the pain in the large joints was progressively aggravated. The joint swelling and pain were obviously alleviated after the treatment of methylprednisolone, and the joint mobility was gradually recovered. Lessons: CRS after CAR-T therapy can manifest as a high fever with swelling and pain in the large joints of the limbs, similar to rheumatoid arthritis. Tocilizumab can lower the body temperature, but it has no significant effect on arthritis. Glucocorticoids can rapidly alleviate joint swelling and pain.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] Cytokine release syndrome complicated with rhabdomyolysis after chimeric antigen receptor T-cell therapy: A case report
    Zhang, Lan
    Chen, Wei
    Wang, Xiao-Min
    Zhang, Shu-Qing
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (26) : 9398 - 9403
  • [2] Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy
    Acharya, Utkarsh H.
    Dhawale, Tejaswini
    Yun, Seongseok
    Jacobson, Caron A.
    Chavez, Julio C.
    Ramos, Jorge D.
    Appelbaum, Jacob
    Maloney, David G.
    EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (03) : 195 - 205
  • [3] Recent advances in the prevention and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
    Shi, Xiaoxue
    Wu, Hongfang
    EUROPEAN JOURNAL OF INFLAMMATION, 2022, 20
  • [4] Recent advances in the prevention and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
    Shi, Xiaoxue
    Wu, Hongfang
    EUROPEAN JOURNAL OF INFLAMMATION, 2022, 20
  • [5] Prognostic Significance of Cytokine Release Syndrome in B Cell Hematological Malignancies Patients After Chimeric Antigen Receptor T Cell Therapy
    Dong, Rujiao
    Jiang, Songfu
    Chen, Yi
    Ma, Yongyong
    Sun, Lan
    Xing, Chongyun
    Zhang, Shenghui
    Yu, Kang
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2021, 41 (12) : 469 - 476
  • [6] Extracorporeal cytokine removal in chimeric antigen receptor T-cell therapy associated cytokine release syndrome in patient with acute lymphoblastic leukemia. Case report
    Shchekina, Antonina E.
    Galstyan, Gennadii M.
    Gavrilina, Olga A.
    Arapova, Natalia M.
    Bronyakina, Svetlana Iu
    Kotova, Ekaterina S.
    Troitskaya, Vera V.
    Parovichnikova, Elena N.
    Maschan, Mikhail A.
    Savchenko, Valerii G.
    TERAPEVTICHESKII ARKHIV, 2021, 93 (07) : 811 - 817
  • [7] Pleural cavity cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy A case report
    Ding, Lijuan
    Hu, Yongxian
    Zhao, Kui
    Wei, Guoqing
    Wu, Wenjun
    Wu, Zhao
    Xiao, Lei
    Huang, He
    MEDICINE, 2018, 97 (07)
  • [8] Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy
    Lina Zhang
    Shuai Wang
    Ji Xu
    Run Zhang
    Han Zhu
    Yujie Wu
    Liying Zhu
    Jianyong Li
    Lijuan Chen
    Experimental Hematology & Oncology, 10
  • [9] Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy
    Zhang, Lina
    Wang, Shuai
    Xu, Ji
    Zhang, Run
    Zhu, Han
    Wu, Yujie
    Zhu, Liying
    Li, Jianyong
    Chen, Lijuan
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
  • [10] Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia A case report
    Zi, Fu Ming
    Ye, Long Long
    Zheng, Ji Fu
    Cheng, Jing
    Wang, Qing Ming
    MEDICINE, 2021, 100 (19) : E25786